Effectiveness of vaginal versus oral progesterone therapy in patients with endometrial hyperplasia: a randomized clinical trial
In brief
In 75 women, vaginal and oral progesterone reduced endometrial thickness similarly
In this randomized trial of women with endometrial hyperplasia without atypia and abnormal bleeding, thickness decreased after three months of vaginal progesterone or oral medroxyprogesterone, with no significant difference between groups. The findings suggest similar short-term effects, but only 75 of 80 participants were evaluated, and longer-term outcomes remain unknown.
- Journal
- BMC women's health (Q1)
- Published
- 21 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Afsaneh Tehranian, Zahra Mollaamin, Faezeh Aghajani, Hadith Rastad, Akram Ghahghaei-Nezamabadi
- PMID
- 43040524
- DOI
- 10.1186/s12905-026-04738-y
Why clinicians should know about it
- Picked for Obstetrics and Gynecology (paper of the day, 19 November 2026): Randomized comparison of progesterone routes for hyperplasia and abnormal bleeding
Abstract
BACKGROUND: Progesterone therapy is the main drug for the treatment of endometrial hyperplasia as a precursor of endometrial cancer. Considering the side effects of systemic progesterone use, we decided to compare the effectiveness and side effects of vaginal use versus oral use. METHODS: This parallel group randomized clinical trial was conducted among 80 women with EH, without atypia, and abnormal uterine bleeding (AUB). Participants were allocated to two groups. Participants in group I received MPA, 2 tablets (5 mg) orally for 14 days per month for 3 months. Participants in group II obtained a 100 mg soft gelatin Progesterone capsule for vaginal use at the same time. 3-4 weeks after the completion of the treatment, the patient's endometrial thicknesses were measured, and endometrial samples were obtained. RESULTS: Finally, 39 and 36 participants were evaluated from groups I and II. The mean endometrial thickness significantly decreased after the intervention compared to before in each group (All p < 0.05), but no statistically significant difference was seen (P = 0.37) between groups. CONCLUSION: The clinical and histologic effects of vaginal MP are the same as MPA, after three cycles of treatment of EH without atypia. TRIAL REGISTRATION: IRCT20140820018866N8. Registered 10/11/2019 Prospectively registered, https//www.irct.ir/trial/41,581.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.